Trending Tickers: $EVGO Buyout Proposal, $MWH Power-Infrastructure Acquisition, $NRIX Sanofi Setback

This week, several stocks caught investors’ attention, driven by significant developments and market momentum. Here’s the breakdown of this week’s trending stocks:

EVgo ($EVGO): Controlling Shareholder Proposes a Buyout

EVgo disclosed on November 2 that LS Power had offered to acquire the EV charging company’s Class A shares it does not already own for $2 per share in cash. LS Power already holds approximately 56% of EVgo’s voting power. In its proposal letter, LS Power said the price represented a 59% premium to EVgo’s October 30 closing price.

EVgo operates public fast-charging stations for electric vehicles, so the proposal would take a company involved in expanding charging infrastructure out of the public market. The offer is unsolicited and nonbinding. EVgo’s board has formed a committee of independent directors to assess it, and LS Power says it will move forward only if that committee recommends the transaction. No purchase agreement has been signed.

LS Power has also said it is interested only in buying the shares it does not own, rather than selling its stake as part of another change-of-control transaction. That makes the independent committee’s review especially important for public shareholders. Its response, and any subsequent agreement on price and terms, are the next developments to watch.

Stock Price Reaction

$EVGO rose 46.83% on Monday, November 2, closing at $1.85. Shares remained below the proposed $2 cash price, reflecting uncertainty over whether the committee and LS Power will reach a binding deal.

SOLV Energy ($MWH): Buying More Power-Grid Construction Capacity

SOLV Energy announced on November 2 that it had completed the acquisition of ASB Energy Services for approximately $45 million, excluding customary closing adjustments. The payment comprised $36 million in cash and $9 million in SOLV shares. ASB, based in Texas, specializes in substation foundations, civil construction, and infrastructure for battery energy storage systems. Its customers include businesses in data centers, energy storage, renewables, and other industries.

SOLV designs, builds, and maintains large power projects. The acquisition adds crews and expertise for high-voltage construction, work needed to connect generation, storage, and large electricity users to the grid. ASB will continue operating under its existing leadership as a SOLV company. That gives SOLV a broader set of services it can perform itself, although the deal does not by itself represent a new data-center contract.

The strategic case is tied to demand for power infrastructure, but the announcement did not disclose ASB’s revenue, earnings, or backlog. Those figures would help investors judge how much the acquisition can contribute to SOLV’s results, beyond adding construction capacity.

Stock Price Reaction

The announcement followed Monday’s close. $MWH gained 11.71% on Tuesday, November 3, closing at $26.81.

Nurix Therapeutics ($NRIX): Sanofi Ends an Experimental Drug Program

Nurix disclosed on November 3 that Sanofi had decided to discontinue the Phase 1 trial of SAR448272 and terminate the program. The experimental oral drug was designed to degrade STAT6, a protein involved in inflammatory signaling. Nurix did not state why Sanofi made the decision, so the announcement does not establish that the drug failed on safety or effectiveness.

The immediate business consequence is the loss of a potential source of future payments: Nurix no longer expects development or commercial milestones, or royalties, from SAR448272. It remains eligible for payments from other programs under its Sanofi collaboration if Sanofi advances them. Nurix also has other work underway, including a Phase 3 trial of its lead drug candidate, bexobrutideg, with Roche.

Nurix said the termination does not change its cash-runway outlook. It reported $1.1 billion in cash, equivalents, and marketable securities as of August 31, which it expects to fund operations into the second half of 2029. That funding supports the remaining pipeline, but the Sanofi decision leaves one fewer partnered drug with a path to future milestones. Progress in the Roche trial and Nurix’s other clinical programs will now carry more weight.

Stock Price Reaction

The news came after Tuesday’s close. $NRIX fell 38.23% on Wednesday, November 4, from $25.82 to $15.95. The size of the decline suggests investors had assigned substantial value to the Sanofi program despite its early stage; it does not indicate that Nurix’s other programs have stopped.

This article is for informational purposes only and is not investment advice or a solicitation to buy or sell securities. The content is based on publicly available information and reflects the author’s opinions as of the publication date, which may change without notice. All investments carry inherent risks, including the potential loss of principal, and past performance is not indicative of future results. Forward-looking statements, including references to projected revenues, market trends, or business developments, are based on current expectations and assumptions. Actual results may differ due to various factors, including regulatory changes, economic conditions, competitive pressures, and unforeseen market fluctuations. Readers should conduct their own research or consult a financial advisor before making investment decisions. BBAE holds no position in the securities mentioned, nor are they compensated by the companies mentioned.